FX and host defense evasion tactics by adenovirus

Molecular Therapy

Volumn 21, Issue 6, 2013, Pages 1109-1111

  Baker, Andrew H ^a   Nicklin, Stuart A ^a   Shayakhmetov, Dmitry M ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIBODY; BLOOD CLOTTING FACTOR 10; CAPSID PROTEIN; CELL RECEPTOR; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; IMMUNOGLOBULIN M ANTIBODY; INTEGRIN; ONCOLYTIC ADENOVIRUS; PROTEOHEPARAN SULFATE; VIRUS PROTEIN; WARFARIN;

ADENOVIRUS; ADENOVIRUS 5; ANTIGEN ANTIBODY COMPLEX; ANTINEOPLASTIC ACTIVITY; CELL INTERACTION; CELL TRANSPORT; COMPLEMENT ACTIVATION; DEFENSE MECHANISM; ERYTHROCYTE; GENE MUTATION; GENE TARGETING; GENETIC TRANSDUCTION; HOST RESISTANCE; IMMUNE EVASION; IN VIVO STUDY; INTERNALIZATION; INTRACELLULAR SIGNALING; KUPFFER CELL; LIVER CELL; MOLECULAR MECHANICS; NOTE; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; THROMBOCYTE; VIRAL GENE THERAPY; VIROTHERAPY; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS PARTICLE;

ADENOVIRIDAE;

EID: 84878597849     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.100     Document Type: Note

References (30)

1. Xu, Z, Qiu, Q, Tian, J, Smith, JS, Conenello, GM, Morita, T et al. (2013). Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat Med 19: 452-457.
2. Bergelson, JM, Cunningham, JA, Droguett, G, KurtJones, EA, Krithivas, A, Hong, JS et al. (1997). Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320-1323.
3. Tomko, RP, Xu, R and Philipson, L (1997). HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackievi-ruses. Proc Natl Acad Sci USA 94: 3352-3356.
4. Wickham, TJ, Mathias, P, Cheresh, DA and Nemerow, GR (1993). Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73: 309-319.
5. Nicklin, SA, Wu, E, Nemerow, GR and Baker, AH (2005). The infuence of adenovirus fber structure and function on vector development for gene therapy. Mol Ther 12: 384-393.
6. Coughlan, L, Alba, R, Parker, AL, Bradshaw, AC, McNeish, IA, Nicklin, SA et al. (2010). Tropism-mod-ifcation strategies for targeted gene delivery using adenoviral vectors. Viruses 2: 2290-2355.
7. Shayakhmetov, DM, Gaggar, A, Ni, SH, Li, ZY and Lieber, A (2005). Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 79: 7478-7491.
8. Kalyuzhniy, O, Di Paolo, NC, Silvestry, M, Hofherr, SE, Barry, MA, Stewart, PL and Shayakhmetov, DM (2008). Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci USA 105: 5483-5488.
9. Waddington, SN, Mcvey, JH, Bhella, D, Parker, AL, Barker, K, Atoda, H et al. (2008). Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132: 397-409.
10. Vigant, F, Descamps, D, Jullienne, B, Esselin, S, Connault, E, Opolon, P et al. (2008). Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol Ther 16: 1474-1480.
11. Bradshaw, AC, Parker, AL, Duffy, MR, Coughlan, L, van Rooijen, N, Kähäri, V-M et al. (2010). Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. PLoS Pathog 6: e1001142.
12. Alba, R, Bradshaw, AC, Coughlan, L, Denby, L, McDonald, RA, Waddington, SN et al. (2010). Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 116: 2656-2664.
13. Alba, R, Bradshaw, AC, Parker, AL, Bhella, D, Waddington, SN, Nicklin, SA et al. (2009). Identifcation of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 114: 965-971.
14. Doronin, K, Flatt, JW, Di Paolo, NC, Khare, R, Kalyuzhniy, O, Acchione, M et al. (2012). Coagulation factor X activates innate immunity to human species C adenovirus. Science 338: 795-798.
15. Waddington, SN, Parker, AL, Havenga, M, Nicklin, SA, Buckley, SMK, Mcvey, JH et al. (2007). Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. J Virol 81: 9568-9571.
16. Alba, R, Bradshaw, AC, Mestre-Frances, N, Verdier, JM, Henaff, D and Baker, AH (2012). Coagulation factor X mediates adenovirus type 5 liver gene transfer in non-human primates (Microcebus muri-nus). Gene Ther 19: 109-113.
17. Appledorn, DM, McBride, A, Seregin, S, Scott, JM, Schuldt, N, Kiang, A et al. (2008). Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors. Gene Ther 15: 1606-1617.
18. Tian, J, Xu, ZL, Smith, JS, Hofherr, SE, Barry, MA and Byrnes, AP (2009). Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo. J Virol 83: 5648-5658.
19. Shayakhmetov, DM, Li, ZY, Ni, S and Lieber, A (2004). Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxic-ity after injection of fber-modifed vectors. J Virol 78: 5368-5381.
20. Di Paolo, NC, Miao, EA, Iwakura, Y, Murali-Krishna, K, Aderem, A, Flavell, RA et al. (2009). Virus binding to a plasma membrane receptor triggers interleu-kin-1 alpha-mediated proinfammatory macrophage response in vivo. Immunity 31: 110-121.
21. Manickan, E, Smith, JS, Tian, J, Eggerman, TL, Lozier, JN, Muller, J et al. (2006). Rapid Kupffer cell death after intravenous injection of adenovirus vectors. Mol Ther 13: 108-117.
22. Nociari, M, Ocheretina, O, Murphy, M and Falck-Pedersen, E (2009). Adenovirus induction of IRF3 occurs through a binary trigger targeting Jun N-terminal kinase and TBK1 kinase cascades and type I interferon autocrine signaling. J Virol 83: 4081-4091.
23. Duffy, MR, Bradshaw, AC, Parker, AL, Mcvey, JH and Baker, AH. (2011). A cluster of basic amino acids in the factor X serine protease mediates surface attachment of adenovirus/FX complexes. J Virol 85: 10914-10919.
24. Di Paolo, NC, van Rooijen, N and Shayakhmetov, DM (2009). Redundant and synergistic mechanisms control the sequestration of blood-borne adenovi-rus in the liver. Mol Ther 17: 675-684.
25. Bradshaw, AC, Coughlan, L, Miller, AM, Alba, R, van Rooijen, N, Nicklin, SA et al. (2012). Biodistribution and infammatory profles of novel penton and hexon double-mutant serotype 5 adenoviruses. J Control Release 164: 394-402.
26. Shashkova, EV, Doronin, K, Senac, JS and Barry, MA (2008). Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus. Cancer Res 68: 5896-5904.
27. Shashkova, EV, May, SM, Doronin, K and Barry, MA (2009). Expanded anticancer therapeutic window of hexon-modifed oncolytic adenovirus. Mol Ther 17: 2121-2130.
28. Xu, Z, Tian, J, Smith, JS and Byrnes, AP (2008). Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol 82: 11705-11713.
29. Cotter, MJ, Zaiss, AK and Muruve, DA (2005). Neutrophils interact with adenovirus vectors via Fc receptors and complement receptor 1. J Virol 79: 14622-14631.
30. Schwartz, JT, Barker, JH, Long, ME, Kaufman, J, Mc-Cracken, J and Allen, LAH (2012). Natural IgM mediates complement-dependent uptake of Francisella tularensis by human neutrophils via complement receptors 1 and 3 in nonimmune serum. J Immunol 189: 3064-3077.